APA (7th ed.) Citation

Ostermann, M., Corteville, D. C., Doi, K., Koyner, J. L., Lamy, A., Li, G., . . . Engelman, D. T. (2025). A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials, 26(1), 1. https://doi.org/10.1186/s13063-025-08895-7

Chicago Style (17th ed.) Citation

Ostermann, Marlies, et al. "A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease from Cardiac Surgery-associated Acute Kidney Injury and Major Adverse Kidney Events (ARTEMIS)." Trials 26, no. 1 (2025): 1. https://doi.org/10.1186/s13063-025-08895-7.

MLA (9th ed.) Citation

Ostermann, Marlies, et al. "A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease from Cardiac Surgery-associated Acute Kidney Injury and Major Adverse Kidney Events (ARTEMIS)." Trials, vol. 26, no. 1, 2025, p. 1, https://doi.org/10.1186/s13063-025-08895-7.